476 related articles for article (PubMed ID: 21972097)
41. Quantifying the early stages of remyelination following cuprizone-induced demyelination.
Stidworthy MF; Genoud S; Suter U; Mantei N; Franklin RJ
Brain Pathol; 2003 Jul; 13(3):329-39. PubMed ID: 12946022
[TBL] [Abstract][Full Text] [Related]
42. Anatomical Distribution of Cuprizone-Induced Lesions in C57BL6 Mice.
Goldberg J; Clarner T; Beyer C; Kipp M
J Mol Neurosci; 2015 Oct; 57(2):166-75. PubMed ID: 26067430
[TBL] [Abstract][Full Text] [Related]
43. Ultrastructural abnormalities and loss of myelinated fibers in the corpus callosum of demyelinated mice induced by cuprizone.
Xiu Y; Cheng GH; Peng C; Wang Y; Li YD; Chao FL; Tang Y
J Neurosci Res; 2017 Aug; 95(8):1677-1689. PubMed ID: 27935632
[TBL] [Abstract][Full Text] [Related]
44. Experimental demyelination caused by primary oligodendrocyte dystrophy. Regional distribution of the lesions in the nervous system of mice [corrected].
Komoly S
Ideggyogy Sz; 2005 Jan; 58(1-2):40-3. PubMed ID: 15884397
[TBL] [Abstract][Full Text] [Related]
45. Lipopolysaccharide delays demyelination and promotes oligodendrocyte precursor proliferation in the central nervous system.
Skripuletz T; Miller E; Grote L; Gudi V; Pul R; Voss E; Skuljec J; Moharregh-Khiabani D; Trebst C; Stangel M
Brain Behav Immun; 2011 Nov; 25(8):1592-606. PubMed ID: 21635946
[TBL] [Abstract][Full Text] [Related]
46. In Vivo Optical Imaging of Myelination Events in a Myelin Basic Protein Promoter-Driven Luciferase Transgenic Mouse Model.
Cao J; Hu Y; Shazeeb MS; Pedraza CE; Pande N; Weinstock D; Polites GH; Zhang W; Chandross KJ; Ying X
ASN Neuro; 2018; 10():1759091418777329. PubMed ID: 29806482
[TBL] [Abstract][Full Text] [Related]
47. N-butyl-β-carboline-3-carboxylate (β-CCB) systemic administration promotes remyelination in the cuprizone demyelinating model in mice.
Vélez-Uriza F; Ordaz RP; Garay E; Cisneros-Mejorado AJ; Arellano RO
Sci Rep; 2024 Jun; 14(1):13988. PubMed ID: 38886527
[TBL] [Abstract][Full Text] [Related]
48. Lack of interferon-beta leads to accelerated remyelination in a toxic model of central nervous system demyelination.
Trebst C; Heine S; Lienenklaus S; Lindner M; Baumgärtner W; Weiss S; Stangel M
Acta Neuropathol; 2007 Dec; 114(6):587-96. PubMed ID: 17940777
[TBL] [Abstract][Full Text] [Related]
49. Transfer of myelin-reactive th17 cells impairs endogenous remyelination in the central nervous system of cuprizone-fed mice.
Baxi EG; DeBruin J; Tosi DM; Grishkan IV; Smith MD; Kirby LA; Strasburger HJ; Fairchild AN; Calabresi PA; Gocke AR
J Neurosci; 2015 Jun; 35(22):8626-39. PubMed ID: 26041928
[TBL] [Abstract][Full Text] [Related]
50. Corticosteroids impair remyelination in the corpus callosum of cuprizone-treated mice.
Clarner T; Parabucki A; Beyer C; Kipp M
J Neuroendocrinol; 2011 Jul; 23(7):601-11. PubMed ID: 21507085
[TBL] [Abstract][Full Text] [Related]
51. Effects of commissural de- and remyelination on motor skill behaviour in the cuprizone mouse model of multiple sclerosis.
Liebetanz D; Merkler D
Exp Neurol; 2006 Nov; 202(1):217-24. PubMed ID: 16857191
[TBL] [Abstract][Full Text] [Related]
52. Phosphatidylcholine 36:1 concentration decreases along with demyelination in the cuprizone animal model and in post-mortem multiple sclerosis brain tissue.
Trépanier MO; Hildebrand KD; Nyamoya SD; Amor S; Bazinet RP; Kipp M
J Neurochem; 2018 Jun; 145(6):504-515. PubMed ID: 29574981
[TBL] [Abstract][Full Text] [Related]
53. Multimodal imaging of subventricular zone neural stem/progenitor cells in the cuprizone mouse model reveals increased neurogenic potential for the olfactory bulb pathway, but no contribution to remyelination of the corpus callosum.
Guglielmetti C; Praet J; Rangarajan JR; Vreys R; De Vocht N; Maes F; Verhoye M; Ponsaerts P; Van der Linden A
Neuroimage; 2014 Feb; 86():99-110. PubMed ID: 23933305
[TBL] [Abstract][Full Text] [Related]
54. Fingolimod does not enhance cerebellar remyelination in the cuprizone model.
Alme MN; Nystad AE; Bø L; Myhr KM; Vedeler CA; Wergeland S; Torkildsen Ø
J Neuroimmunol; 2015 Aug; 285():180-6. PubMed ID: 26198937
[TBL] [Abstract][Full Text] [Related]
55. Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model.
Nystad AE; Torkildsen Ø; Wergeland S
J Neuroimmunol; 2018 Aug; 321():61-65. PubMed ID: 29957389
[TBL] [Abstract][Full Text] [Related]
56. PET imaging of demyelination and remyelination in the cuprizone mouse model for multiple sclerosis: a comparison between [11C]CIC and [11C]MeDAS.
de Paula Faria D; de Vries EF; Sijbesma JW; Dierckx RA; Buchpiguel CA; Copray S
Neuroimage; 2014 Feb; 87():395-402. PubMed ID: 24188813
[TBL] [Abstract][Full Text] [Related]
57. The chemokine receptor CXCR2 is differentially regulated on glial cells in vivo but is not required for successful remyelination after cuprizone-induced demyelination.
Lindner M; Trebst C; Heine S; Skripuletz T; Koutsoudaki PN; Stangel M
Glia; 2008 Aug; 56(10):1104-13. PubMed ID: 18442092
[TBL] [Abstract][Full Text] [Related]
58. 24-hydroxycholesterol replacement rate measured in blood is a non-invasive biomarker of brain demyelination and remyelination in cuprizone-treated mice.
Shankaran M; Mohammed H; Tsang E; Wong PA; Protasio J; Murphy EJ; Bernard F; Chang R; Dellovade T; Turner S; Hellerstein MK
Exp Neurol; 2023 Jun; 364():114395. PubMed ID: 37003487
[TBL] [Abstract][Full Text] [Related]
59. Gene expression in brain during cuprizone-induced demyelination and remyelination.
Morell P; Barrett CV; Mason JL; Toews AD; Hostettler JD; Knapp GW; Matsushima GK
Mol Cell Neurosci; 1998 Nov; 12(4-5):220-7. PubMed ID: 9828087
[TBL] [Abstract][Full Text] [Related]
60. Yokukansan Reduces Cuprizone-Induced Demyelination in the Corpus Callosum Through Anti-inflammatory Effects on Microglia.
Nomura T; Bando Y; You H; Tanaka T; Yoshida S
Neurochem Res; 2017 Dec; 42(12):3525-3536. PubMed ID: 28929408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
